Stocktoria
LENZ Therapeutics, Inc. LENZ
LENZ Therapeutics, Inc. (LENZ) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $19.1M at a -430.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.916 |
| Retained earnings / assets | -0.743 |
| EBIT / assets | -0.298 |
| Equity / liabilities | 13.202 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LENZ | LENZ Therapeutics, Inc. | 2/9 | 15.45 | — | — |
| ALEC | Alector, Inc. | 1/9 | -9.85 | — | -79.1% |
| PTHS | Pelthos Therapeutics Inc. | 4/9 | -1.47 | — | — |
| RLAY | Relay Therapeutics, Inc. | 3/9 | 2.96 | — | +53.4% |
| LCTX | Lineage Cell Therapeutics, Inc. | 3/9 | -12.25 | — | — |
| MGX | Metagenomi Therapeutics, Inc. | 1/9 | -0.61 | — | -51.8% |
| ELUT | ELUTIA INC. | 4/9 | -8.05 | 0.8 | -15% |
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
FAQ
Is LENZ financially healthy?
LENZ Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does LENZ pay a dividend?
No, LENZ Therapeutics, Inc. does not currently pay a dividend.
How profitable is LENZ?
In FY2025, LENZ Therapeutics, Inc. had a net margin of -430.3% and a return on equity of -28.9%.
What is the analyst price target for LENZ?
The average Wall-Street price target for LENZ Therapeutics, Inc. is $32.00, about 534.9% above the recent price, from 7 analysts (consensus: strong buy).
Is LENZ a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on LENZ Therapeutics, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.